Trial · NCT05607615
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety assessments to include incidence of Adverse Events and Serious Adverse Events | up to 24 weeks | Incidence of AEs, SAEs, incidence of abnormal laboratory test results, abnormal ECGs, abnormal physical exams, abnormal vital signs and abnormal hearing assessments assessments |
| Secondary | Mean change in total ADAS-Cog-14 score from Baseline | Week 12 and 24 | Memory, Language, and Executive Function |
| Secondary | Change in CDR-SB from Baseline | Weeks 12 and 24 | Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and Hobbies, and Personal Care |
| Secondary | Change in MMSE-2:SV total score from Baseline | Weeks 12 and 24 | Orientation, Attention, Memory, Language, and Visual-Spatial Skills |
| Secondary | Change in ADCS-CGIC from Baseline | Weeks 12 and 24 | Cognitive, Behavior, and Social and Daily Functioning |
| Secondary | Change in ADCS-ADL from Baseline | Weeks 12 and 24 | Basic Activities of Daily Living Items and Instrumental Activities of Daily Living Items |
| Other | Change in combined Z-scores from Baseline (V2) to Weeks 12 (V5) and 24 (V8) on ADAS-Cog-14 | At week 12 and week 24 | Memory, Language, and Executive Function |
| Other | Change in combined Z-scores from Baseline (V2) to Weeks 12 (V5) and 24 (V8) on CDR-SB | At week 12 and week 24 | Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and Hobbies, and Personal Care |
| Other | Change in combined Z-scores from Baseline (V2) to Weeks 12 (V5) and 24 (V8) on MMSE-2:SV | At week 12 and week 24 | Orientation, Attention, Memory, Language, and Visual-Spatial Skills |
| Other | Peak Plasma Concentration (Cmax) | Weeks 4, 8, 12, and 24 | Maximum concentration, determined directly from individual concentration-time data |
| Other | Time to the Maximum concentration (Tmax) | Weeks 4, 8, 12, and 24 | Time of the maximum concentration, determined directly from individual concentration-time data |
| Other | Area under the plasma concentration versus time curve (AUC) | Weeks 4, 8, 12, and 24 | Area under the concentration-time curve from time-zero to the time of the last quantifiable concentration |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05607615/registered